会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明专利
    • Patch preparation containing bisoprolol
    • 包含双酚的配方制剂
    • JP2011195565A
    • 2011-10-06
    • JP2011014534
    • 2011-01-26
    • Nitto Denko CorpToa Eiyo Ltdトーアエイヨー株式会社日東電工株式会社
    • IWAO YOSHIHIROMATSUOKA KENSUKEAOYANAGI KAZUHIROHARIMA JUNKONNO MASAKATSU
    • A61K31/138A61K9/70A61K47/06A61K47/14A61P9/06A61P9/10A61P9/12
    • A61K31/138A61F13/02A61F13/0253A61F13/0259A61F2013/00646A61K9/703A61K9/7053
    • PROBLEM TO BE SOLVED: To provide a patch preparation well restrained in the decrease of drug content by generation of oozing and protrusion of the component of self-adhesive layer from the exposed area of the self-adhesive layer of the patch preparation in storage and oozing of bisoprolol or its salts from the self-adhesive layer.SOLUTION: Each shape of the flat surfaces of the patch preparation, a support, a peeling liner and the self-adhesive layer are made rectangle and a salient is made on the surface of the support at the edge of the rectangle of the patch preparation. It is also possible to make a central part and a peripheral part on the patch preparation and the salient is made at the corners of the rectangle of the central part, and further it is possible to make a built-up articulated portion having a thickness of thinner than that at the salient of the patch preparation between the neighboring not less than two salients. When a back split is made on the peeling liner, it must not go through the salient at the corner of the rectangle.
    • 要解决的问题:为了提供在药物含量降低方面良好抑制的贴剂制剂,通过产生渗出并将自粘层的组分从储存和渗出的贴剂的自粘层的暴露区域突出 的比索洛尔或其盐。解决方案:贴片制剂,支撑体,剥离衬垫和自粘层的平坦表面的每个形状被制成矩形,并且在表面上形成凸起 支持在补丁准备的矩形的边缘。 也可以在贴片制剂上形成中心部分和周边部分,并且在中心部分的矩形的角部形成突出部,并且还可以制成具有厚度的 稀薄比贴片制剂的突出点之间相邻不少于两种。 当在剥皮衬垫上进行背部分割时,不得通过矩形角落处的凸面。
    • 2. 发明专利
    • Percutaneous administration device of bisoprolol
    • 双氯酚的经皮给药装置
    • JP2013199486A
    • 2013-10-03
    • JP2013119229
    • 2013-06-05
    • Nitto Denko Corp日東電工株式会社Toa Eiyo Ltdトーアエイヨー株式会社
    • IWAO YOSHIHIROMATSUOKA KENSUKEOKADA KATSUHIROMINAMI KUNIHIROYUASA SHUICHIRO
    • A61K31/138A61K9/70A61K47/32A61K47/34A61P9/06A61P9/10A61P9/12
    • A61K31/138A61K9/7053A61K9/7061
    • PROBLEM TO BE SOLVED: To provide a percutaneous administration device reduced in skin stimulation when applied, in particular, when reapplied, and capable of administrating an amount of bisoprolol effective to therapy or prophylaxis continuously to a living organism.SOLUTION: A percutaneous administration device 10 for bisoprolol includes a support body 1 and a pressure-sensitive adhesive layer 2 laminated on one surface of the support body 1, and the bisoprolol is contained in the pressure-sensitive adhesive layer 2, the maximum value of bisoprolol releasing speed is 30 μg/cm/hour or less in the period from the time just after applied onto a skin up to the lapse of 24 hours, and the bisoprolol releasing speed is 10 μg/cm/hour or less in the period from the time just after applied onto the skin up to the lapse of 24 hours. The skin is thereby not only restrained from being stimulated by the bisoprolol, but also the risk of a side effect such as bradycardia and vertigo to be caused due to excessive depression is eliminated to secure sufficient safety.
    • 要解决的问题:提供一种经皮给药装置,特别是在应用时,特别是重新施用时,能够施用一定量的比索洛尔,有效治疗或预防生物体的皮肤刺激。解决方案:经皮给药装置10 对比索洛尔包括支撑体1和层叠在支撑体1的一个表面上的压敏粘合剂层2,并且比索洛尔包含在压敏粘合剂层2中,比索洛尔释放速度的最大值为30μg/ cm 3 /小时以下,在从施用到皮肤上直到24小时后的时间段内,比索洛尔释放速度在从施加到皮肤上起算之后的时间内为10μg/ cm 3 /小时以下 皮肤长达24小时。 因此,皮肤不仅可以抑制比索洛尔的刺激,而且消除由于过度抑郁引起的副作用(如心动过缓和眩晕)的风险,以确保足够的安全性。
    • 4. 发明专利
    • Transdermal administration device for bisoprolol
    • 双酚A的超导管理装置
    • JP2008247899A
    • 2008-10-16
    • JP2008057691
    • 2008-03-07
    • Nitto Denko CorpToa Eiyo Ltdトーアエイヨー株式会社日東電工株式会社
    • OKADA KATSUHIROMINAMI KUNIHIROIWAO YOSHIHIROYUASA SHUICHIROMATSUOKA KENSUKE
    • A61K31/138A61K9/70A61P9/06A61P9/10A61P9/12A61P43/00
    • A61K31/138A61K9/7053A61K9/7061
    • PROBLEM TO BE SOLVED: To provide a transdermal administration device which shows a relieved skin irritation at the application, particularly at the peeling, and enables the continuous administration of a therapeutically or preventively effective amount of bisoprolol to a living body. SOLUTION: The transdermal administration device 10 for bisoprolol is equipped with a supporting medium 1 and a pressure-sensitive adhesive layer 2 which is layered on one surface of the supporting medium 1 and contains bisoprolol in the pressure-sensitive adhesive layer 2. The maximum speed of releasing bisoprolol within 24 hours immediately after the application to the skin is not higher than 30 μg/cm 2 /hour, and the speed of releasing bisoprolol at the point 24 hours after the application to the skin is not higher than 10 μg/cm 2 /hour. Thus, not only the skin irritation by bisoprolol is restrained, but also the possibility of side effects such as bradycardia or dizziness by excessive antihypertension are excluded, ensuring sufficient safety. COPYRIGHT: (C)2009,JPO&INPIT
    • 待解决的问题:提供一种透皮给药装置,其在使用时特别是在剥离时显示缓解的皮肤刺激,并且能够将生物体上治疗或预防有效量的比索洛尔连续给药。

      解决方案:比索洛尔的透皮给药装置10配备有支撑介质1和压敏粘合剂层2,其在层压在支撑介质1的一个表面上并在压敏粘合剂层2中含有比索洛尔。 施用于皮肤后24小时内释放比索洛尔的最大速度不高于30μg/ cm 2 / SP /小时,施用后24小时释放比索洛尔的速度 皮肤不高于10μg/ cm 2 / SP /小时。 因此,不仅抑制了比索洛尔的皮肤刺激,而且排除了通过过度抗高血压引起的心动过缓或眩晕等副作用的可能性,确保了足够的安全性。 版权所有(C)2009,JPO&INPIT